JP2009509920A5 - - Google Patents

Download PDF

Info

Publication number
JP2009509920A5
JP2009509920A5 JP2008525976A JP2008525976A JP2009509920A5 JP 2009509920 A5 JP2009509920 A5 JP 2009509920A5 JP 2008525976 A JP2008525976 A JP 2008525976A JP 2008525976 A JP2008525976 A JP 2008525976A JP 2009509920 A5 JP2009509920 A5 JP 2009509920A5
Authority
JP
Japan
Prior art keywords
disorder
pain
post
psychiatric disorders
neurological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008525976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009509920A (ja
JP5031745B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2005/028760 external-priority patent/WO2006020879A1/en
Application filed filed Critical
Priority claimed from PCT/US2006/005246 external-priority patent/WO2007021308A1/en
Publication of JP2009509920A publication Critical patent/JP2009509920A/ja
Publication of JP2009509920A5 publication Critical patent/JP2009509920A5/ja
Application granted granted Critical
Publication of JP5031745B2 publication Critical patent/JP5031745B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008525976A 2005-08-12 2006-02-15 代謝型グルタミン酸受容体増強性イソインドロン Expired - Fee Related JP5031745B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2005/028760 WO2006020879A1 (en) 2004-08-13 2005-08-12 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
USPCT/US2005/028760 2005-08-12
PCT/US2006/005246 WO2007021308A1 (en) 2005-08-12 2006-02-15 Metabotropic glutamate-receptor-potentiating isoindolones

Publications (3)

Publication Number Publication Date
JP2009509920A JP2009509920A (ja) 2009-03-12
JP2009509920A5 true JP2009509920A5 (enExample) 2009-04-23
JP5031745B2 JP5031745B2 (ja) 2012-09-26

Family

ID=36464390

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008525977A Pending JP2009509921A (ja) 2005-08-12 2006-02-15 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用
JP2008525976A Expired - Fee Related JP5031745B2 (ja) 2005-08-12 2006-02-15 代謝型グルタミン酸受容体増強性イソインドロン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008525977A Pending JP2009509921A (ja) 2005-08-12 2006-02-15 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用

Country Status (4)

Country Link
EP (2) EP1912940A1 (enExample)
JP (2) JP2009509921A (enExample)
CN (2) CN101309905A (enExample)
WO (2) WO2007021308A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US20080139846A1 (en) * 2006-09-01 2008-06-12 Astrazeneca Ab New Process 298
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
WO2008130853A1 (en) * 2007-04-17 2008-10-30 Astrazeneca Ab Hydrazides and their use as metabotropic glutamate receptor potentiators - 681
US20100197800A1 (en) * 2007-04-23 2010-08-05 Richard Friedman Treatment and/or Prevention of Presbycusis by Modulation of Metabotropic Glutamate Receptor 7
AU2008257559B2 (en) 2007-05-25 2013-10-10 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (MGLU2 receptor)
TW200911255A (en) * 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
WO2009004430A1 (en) * 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
US7790760B2 (en) * 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
AU2010221980A1 (en) * 2009-03-11 2011-10-13 Msd K.K. Novel isoindolin-1-one derivative
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
PH12012500669A1 (en) * 2009-10-09 2018-02-07 Celgene Corp Processes for the preparation of 2-(1-phenylethyl) isoindolin-1-one compounds
US8507521B2 (en) 2009-11-02 2013-08-13 Merck Sharp + Dohme B.V. Heterocyclic derivatives
WO2011084098A1 (en) * 2010-01-07 2011-07-14 Astrazeneca Ab Process for making a metabotropic glutamate receptor positive allosteric modulator - 874
US8314120B2 (en) 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
US8664214B2 (en) 2010-03-30 2014-03-04 AbbVie Deutschland GmbH & Co. KG Small molecule potentiators of metabotropic glutamate receptors I
WO2012062759A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
PT2649069E (pt) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2
JP5852665B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
US8895571B2 (en) 2011-10-14 2014-11-25 Incyte Corporation Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors
AU2012328476B2 (en) * 2011-10-28 2017-03-30 Vanderbilt University Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
EA034440B1 (ru) 2015-10-29 2020-02-07 Эффектор Терапьютикс, Инк. СОЕДИНЕНИЯ ПИРРОЛО-, ПИРАЗОЛО-, ИМИДАЗОПИРИМИДИНА И ПИРИДИНА, КОТОРЫЕ ИНГИБИРУЮТ Mnk1 И Mnk2
CA3002877A1 (en) 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
CN105837557A (zh) * 2016-05-05 2016-08-10 青岛辰达生物科技有限公司 一种用于治疗ii型糖尿病的阿格列汀的制备方法
CN106279182B (zh) * 2016-07-29 2019-06-07 中国药科大学 一种吡咯并[2，1-a]异吲哚酮类化合物及其合成方法
EP3582776B1 (en) 2017-02-14 2023-11-08 Effector Therapeutics, Inc. Piperidine-substituted mnk inhibitors and methods related thereto
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
EP3459939A1 (en) * 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7
KR20210102211A (ko) 2018-10-24 2021-08-19 이펙터 테라퓨틱스, 인크. Mnk 억제제의 결정질 형태
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
CN110498759A (zh) * 2019-09-12 2019-11-26 天津瑞岭化工有限公司 异吲哚啉酮类化合物的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE620654C (de) * 1933-04-29 1935-10-24 Smith & Sons Ltd S Geschwindigkeitsanzeiger
US3579524A (en) * 1968-06-05 1971-05-18 Miles Lab 2-aminoalkyl derivatives of phthalimidines
US3993617A (en) * 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
DE3717561A1 (de) * 1987-05-25 1988-12-08 Thomae Gmbh Dr K Indol-, isochinolin- und benzazepinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH02184667A (ja) * 1989-01-11 1990-07-19 Meiji Seika Kaisha Ltd Ｎ，ｎ’―ジ置換ピペラジル誘導体及びそれを有効成分とする排尿障害改善剤
TW219935B (enExample) * 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
CN1158264C (zh) * 1997-11-21 2004-07-21 Nps药物有限公司 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂
PT1260512E (pt) * 2000-02-29 2007-10-10 Mitsubishi Pharma Corp ''novos derivados de amida cíclicos''
DE10031391A1 (de) * 2000-07-03 2002-02-07 Knoll Ag Bicyclische Verbindungen und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie
WO2002006231A1 (en) * 2000-07-18 2002-01-24 Sumitomo Pharmaceuticals Co., Ltd. Serotonin reuptake inhibitors
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
JP2007510629A (ja) * 2003-10-22 2007-04-26 イーライ リリー アンド カンパニー 新規ｍｃｈ受容体アンタゴニスト
JP2007519754A (ja) * 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
CN1934094A (zh) * 2004-03-05 2007-03-21 万有制药株式会社 二芳基取代杂环5元环衍生物
JP4883296B2 (ja) * 2004-03-05 2012-02-22 日産化学工業株式会社 イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators

Similar Documents

Publication Publication Date Title
JP2009509920A5 (enExample)
JP2009509921A5 (enExample)
RU2009147708A (ru) Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842
JP2013544277A5 (enExample)
Wareham et al. The nitric oxide-guanylate cyclase pathway and glaucoma
JP2012530129A5 (enExample)
WO2009117515A8 (en) Novel compounds advantageous in the treatment of central nervous system diseases and disorders
PH12012501514A1 (en) (2s, 3r)-n-(2-((3-pyridinyl)methyl)-1-azabycyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof
ME01903B (me) Hetrociklički sulfonamidi, njihova upotreba i farmaceutski pripravci
WO2005075436A3 (en) Novel inhibitors of glutaminyl cyclase
WO2010039186A3 (en) Benzoxazoles useful as faah modulators and uses thereof
MX2016008842A (es) Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos.
EP2604602A4 (en) HETEROARYL PYRAZOLE DERIVATIVE
MX2010001824A (es) Heterociclos como moduladores de canal de potasio.
WO2014037416A3 (en) Compositions for treating parkinson's disease
GB2462235A (en) NMDA and MC receptor antagonists exhibiting neuroprotective and memory enhancing activities
MY154877A (en) 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamateric synaptic responses
WO2006113471A3 (en) N-alkyl-azacycloalkyl nmda/nr2b antagonists
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
MX362532B (es) Derivados de 1,7-naftiridina.
JP2016506939A5 (enExample)
JP2014500885A5 (enExample)
RU2016132574A (ru) Органические соединения
Starkstein et al. Neurological and psychiatric aspects of emotion
JP2008519056A5 (enExample)